Jupiter Neurosciences (JUNS) vs Sunshine Biopharma (SBFM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sunshine Biopharma is the larger company by market cap ($1.8 million vs $1.6 million), about 1.1 times the size. On valuation, Sunshine Biopharma trades at a lower forward P/E (0.0x vs 20.6x for Jupiter Neurosciences). Sunshine Biopharma converts more of its revenue into profit, with a net margin of -16.5% versus -39662.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JUNS | SBFM |
|---|---|---|
| Share price | $1.24 | $2.23 |
| Market cap | $1.63M | $1.84M |
| 1-day change | -18.75% | -5.11% |
| Forward P/E | 20.58 | 0.01 |
| EPS (TTM) | $-22.53 | $-620.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $21.80K | $36.31M |
| Revenue growth (YoY) | — | +4.11% |
| Net income (latest FY) | $-8.64M | $-5.98M |
| Gross margin | 80.59% | 33.76% |
| Operating margin | -40873.19% | -17.15% |
| Net margin | -39662.77% | -16.46% |
| 52-week high | $97.73 | $464.00 |
| 52-week low | $1.20 | $2.23 |
| Distance from 52-week high | -98.74% | -99.52% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2411.21% |
| Average volume | 69.86K | 301.48K |
| Shares outstanding | 1.32M | 823.77K |
| Employees | 5 | 50 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sunshine Biopharma is more profitable, keeping -16.5 cents of every revenue dollar as net income versus -39662.8 cents for Jupiter Neurosciences.
About Jupiter Neurosciences
JUNS stock →Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Sunshine Biopharma
SBFM stock →Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees
JUNS vs SBFM FAQ
Which is bigger, Jupiter Neurosciences or Sunshine Biopharma?
Sunshine Biopharma (SBFM) is larger, with a market capitalization of $1.84M compared with $1.63M for Jupiter Neurosciences (JUNS).
Are Jupiter Neurosciences and Sunshine Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.